Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy

Medical Oncology

Volumn 30, Issue 4, 2013, Pages

  Thomas, Betsan M ^a   Smith, Christian ^b   Evans, Jessica ^c   Button, Michael R ^b   Kumar, Satish ^b   Palaniappan, Nachi ^b   Staffurth, John ^c   Tanguay, Jacob S ^b   Lester, Jason F ^b  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b Velindre NHS Trust   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Docetaxel; Metastatic castrate resistant prostate cancer; Prostate specific antigen halving time; Prostate specific antigen nadir; Prostate specific antigen progression

Indexed keywords

DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; TAXOID;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; LETHARGY; MALE; METASTASIS; MIDDLE AGED; NEUROPATHY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT RESPONSE; VERY ELDERLY; CASTRATION; DISEASE COURSE; DISEASE FREE SURVIVAL; GENETICS; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CASTRATION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84883608995     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0719-0     Document Type: Article

References (30)

1. Cancer Research UK. Prostate cancer incidence statistics. Available at http://www.cancerresearchuk.org/cancer-info/cancerstats/types/prostate/ incidence.
2. Prostate Cancer Triallists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491-8.
3. Chamberlain J, Melia J, Moss S. The diagnosis, management, treatment and cost of prostate cancer in England and Wales. Health Technol Assess. 1997; 1(3).
4. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. NEJM. 1989;321:419-24. (Pubitemid 19211484)
5. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchidectomy with or without flutamide for metastatic prostate cancer. NEJM. 1998;339:1036-42. (Pubitemid 28457865)
6. Sartor AO, Tangen CM, Hussain MHA, et al. Antiandrogen withdrawal in castrate refractory prostate cancer. Cancer. 2008;112(11):2393-400.
7. Tannock I, de Wit R, Berry WR et al for the TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer 2004; 351:1502-1512.
8. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. NEJM. 2011;364:1995-2005.
9. Scher HI, Fizazi K, Saad F et al AFFIRM Investigators. NEJM 2012; 367(13):1187-97.
10. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54.
11. Higano CS, Schellhammer PF, Small E, et al. Integrated data from 2 randomised, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(6):3670-9.
12. Parker C, Nilsson S, Heinrich D et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 30(18).
13. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(4):591-8.
14. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-83. (Pubitemid 37220457)
15. Park YH, Hwang IS, Jeong CW, Kim HH, Lee SE, Kwak C. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer. J Urol. 2009;181:2520-4.
16. Kwak C, Jeong SJ, Park MS, Lee SE. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol. 2002;168:995-1000.
17. Morote J, Trilla E, Esquana S, Abascal JM, Raventos J. Nadir prostate specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Cancer. 2004;108:877-81. (Pubitemid 38112617)
18. Benaim EA, Pace CM, Lam PM, Roeeborn CG. Nadir prostate specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology. 2002;59:73-8. (Pubitemid 34059310)
19. Huang SP, Bao BY, Wu MT, et al. Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate. 2011;71:1189-97.
20. Arai Y, Yoshiri T, Yoshida O. Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. J Urol. 1990;144:1415-9.
21. Cooper EH, Armitage TG, Robinson MR, et al. Prostate specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer. 1990;66:1025-8. (Pubitemid 20293000)
22. Park BJ, Lee YG, Ahn HK. Prognostic significance of prostate specific antigen two months after maximal androgen blockade in metastatic prostate cancer. Korean J Urol. 2003;44:855-60.
23. Sasaki T, Onishi T, Hoshina A. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis. Prostate Cancer Prostatic Dis. 2011;14:248-52.
24. Choueiri TK, Xie W, D'Amico AV, et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009;115:981-7.
25. Hong SY, Cho DS, Kim SI, Ahn HS, Kim SJ. Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer. Korean J Urol. 2012;53(9):607-13.
26. Huang SP, Bao BY, Wu MT, et al. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy. Ageing Male. 2012;15:34-41.
27. Hori S, Jabbar T, Kachroo N, Vasconcelos JC, Robson CN, Gnanapragasam VJ. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. J Cancer Res Clin Oncol. 2011;137:235-41.
28. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006;98:516-21. (Pubitemid 43898814)
29. Porcaro AB, Sava T, Merlin F, et al. Hormone refractory metastatic prostate cancer: does PSA halving time during docetaxel treatment have a prognostic role. Eur Urol. 2008;7(3):231.
30. Andren O, Fall K, Franzen L, Andersson SO, Johansson JE, Rubin MA. How well does the Gleason score predict prostate cancer death? A 20-year follow-up of a population based cohort in Sweden. J Urol. 2006;175:1337-40.